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Assessing the pathological relevance of SPINK1
promoter variants
Arnaud Boulling1,2, Heiko Witt3, Giriraj Ratan Chandak4, Emmanuelle Masson1,5, Sumit Paliwal4,
Seema Bhaskar4, D Nageshwar Reddy6, David N Cooper7, Jian-Min Chen*,1,8 and Claude Fe ´rec1,2,5,8
The SPINK1 gene, encoding the human pancreatic secretory trypsin inhibitor, is one of the major genes involved in
predisposition to chronic pancreatitis (CP). In this study we have assessed the potential functional impact of 11 SPINK1
promoter variants by means of both luciferase reporter gene assay and electrophoretic mobility shift assay (EMSA), using human
pancreatic COLO-357 cells as an expression system. The 11 promoter variants were found to be separable into three distinct
categories on the basis of the reporter gene assay results viz loss-of-function, gain-of-function and functionally neutral. These
ﬁndings, which were validated by EMSA, concurred with data from previous deletion studies and DNase I footprinting assays.
Further, binding sites for two transcription factors, HNF1 and PTF1, were newly identiﬁed within the SPINK1 promoter by virtue
of their being affected by speciﬁc variants. Combining the functional data with epidemiological data (derived by resequencing
the SPINK1 promoter region in French, German and Indian CP patients and controls), then allowed us to make meaningful
inferences as to each variant’s likely contribution to CP. We conclude that only the three promoter variants associated with a
loss-of-function (ie, 53C4T, 142T4C and 147A4G) are likely to be disease-predisposing alterations.
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INTRODUCTION
Chronic pancreatitis (CP) is a recurring inﬂammatory disease of the
pancreas. Advances in molecular genetics made over the last 15 years
have contributed signiﬁcantly to our understanding of the patho-
genesis of CP. In particular, the identiﬁcation of gain-of-function missense
and copy-number mutations in the cationic trypsinogen (PRSS1;
MIM# 276000) gene,1–2 and loss-of-function variants in the pan-
creatic secretory trypsin inhibitor (SPINK1; MIM# 167790) and
chymotrypsin C (CTRC; MIM# 601405) genes3–5 has highlighted
the pivotal role of prematurely activated pancreatic trypsin in the
aetiology of CP (for a recent review, see Chen and Fe ´rec6).
To date, a wide range of different types of SPINK1 mutation have
been reported. Of these, the splicing (c.87+1G4A7 and
c.194+2T4C3) and frameshift (c.27delC7 and c.98_99insA8)m u t a -
tions, the gross deletions (c.1-320_c.55+961del1336bp9 and deletion
of the entire gene10), and the p.M1T initiation codon mutation3
represent unequivocal loss-of-function mutations. Although the
causative variant within the common p.N34S-containing haplotype
still remains to be identiﬁed,11–12 the rare SPINK1 missense mutations
have all been experimentally shown to be deleterious.13–15 By contrast,
the pathological relevance of the known SPINK1 promoter variants is
largely unknown. The underlying reasons for this may be that (i) most
of the SPINK1 promoter variants are rare or even unique to particular
individuals, (ii) our knowledge of the regulatory elements in the
SPINK1 gene promoter is still fairly rudimentary16 and (iii) there are
technical difﬁculties inherent in the functional characterization of
promoter variation that invariably need to be overcome.17 In this
study we (a) carried out resequencing of the SPINK1 proximal
promoter in CP patients and controls from three different popula-
tions, (b) performed a thorough functional analysis of the currently
known SPINK1 promoter variants and (c) integrated the resulting
data in order to assess the pathological relevance of each promoter
variant.
MATERIALS AND METHODS
Resequencing the SPINK1 proximal promoter region
The proximal promoter region of the SPINK1 gene was resequenced in both CP
patients and controls in three different (French, German and Indian) labora-
tories (Supplementary Methods). The 213 French patients (all diagnosed with
idiopathic chronic pancreatitis (ICP) at 20 years or younger), the 439 Indian
patients (292 tropical chronic pancreatitis (TCP), 147 ICP (Supplementary
Methods)), and the 418 German ICP patients (Table 1) have been previously
described.18–19 This work was approved by the local ethical review committees
of each collaborating institution.
SPINK1 promoter variants included in this study
At o t a lo f1 1SPINK1 promoter variants have been reported in the literature.
With the exception of the 253T4C variant, which is a common polymor-
phism,3,20–21 all these promoter variants (ie, 74G, 22C4T, 41G4A,
53C4T, 81C4T, 142T4C, 147A4G, 164G4C, 215G4Aa n d
215G4T; Figure 1a) were included in the analysis reported here. Also
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www.nature.com/ejhgincluded was a novel variant (viz, 170G4A) that was found during the
resequencing analysis of the French patients (Table 1). All 11 promoter variants
studied were numbered relative to the ﬁrst nucleotide 5¢ to the A of the
translational initiation codon, designated –1. NG_008356.1 was used as the
SPINK1 reference sequence.
Construction of reporter plasmids
A DNA fragment spanning 1171 to 1o ft h eSPINK1 promoter region was
PCR ampliﬁed from genomic DNA of a wild-type homozygote, using the
forward primer 5¢-GAGCTCAGAGAAAAGGGACT-3¢ containing a SacI restric-
tion site (underlined) and the reverse primer 5¢-CCATGGCTGAAGTTCTGC
GT-3¢ containing an NcoI restriction site (underlined). The PCR product was
ﬁrst subcloned into pcDNA3.1/V5-His-TOPO (Invitrogen, Cergy-Pontoise,
France). The SPINK1 promoter insert was then excised from the plasmid
mini-prep DNA using SacIa n dNcoI, and cloned into the SacI/NcoIs i t eo f
pGL3-basic Reporter Vector (Promega, Charbonnieres, France). The resulting
pGL3-SPINK1 wild-type construct, which contains the SPINK1 promoter
insert immediately upstream of the translational initiation codon of the
luciferase reporter gene, was used to create the 11 SPINK1 promoter variant
reporter plasmids by site-directed mutagenesis using the Quick Change Site
Directed Mutagenesis Kit (Stratagene, Massy, France). Each construct was
sequence checked in order to conﬁrm that no additional mutations had been
inadvertently introduced.
Cell culture and transfection
Human pancreatic adenocarcinoma (COLO-357) and human embryonic
kidney (HEK 293) cell lines were grown under conditions previously
described.22 Transfections were carried out as previously described,22 using
3.8mg pGL3-basic or pGL3-SPINK1 plus 0.2mg control pRL-CMV vector.
Analysis of SPINK1 mRNA expression in the COLO-357 cells
Quantitative analysis of SPINK1 mRNA expression in the COLO-357 cells was
carried out by quantitative RT-PCR, using the CTRC gene as a control
(Supplementary Methods and Supplementary Table S1).
Luciferase reporter gene assay
At 48h after transfection, cells were washed with phosphate-buffered saline and
lysed with 180ml passive lysis buffer (Promega). After centrifugation, 20ml
supernatant from each sample were added to 100ml luciferase reagent and
100ml Renilla reagent, separately. The relative luciferase activity was determined
by dividing the luminescence of luciferase activity by that of the co-transfected
Renilla. Three to six independent transfections (each using plasmids prepared
from different clones) were carried out for each construct and luciferase assays
were conducted in triplicate for each transfection. The difference between the
luciferase activity of each SPINK1 promoter variant construct and the wild-type
construct was then assessed for signiﬁcance by means of the Student’s t-test.
Electrophoretic mobility shift assay (EMSA)
5¢-Biotin end-labelled probes and unlabelled speciﬁc (SpC), mutant (MuC),
irrelevant (IrC) and cross-competitors (CrC; see Table 2 for deﬁnition of terms)
were purchased from Eurogentec (Angers, France). Oligonucleotide sequences
of the labelled probes and unlabelled SpCs and MuCs are provided in the
Figures. IrC corresponds to c.136_c.165 of the human SPINK1 gene, whereas
the SI CrC corresponds to a 32-bp sequence tract (ie, 5¢-TAAGATATTAA-
TAGTTCACAGCTTTGAGAAAT-3¢) found in the promoter of the human
sucrase-isomaltase (SI) gene that has been experimentally demonstrated to
contain a binding site for hepatocyte nuclear factor 1 (HNF1).23 The human
PRSS1 CrC (138_101 of the gene; NG_001333.2) is homologous to a
pancreas-speciﬁc transcription factor 1 (PTF1) binding sequence in the rat
trypsinogen gene.24
COLO-357 nuclear extracts were prepared using the NE-PER Nuclear and
Cytoplasmic Extraction Reagent kit (Pierce, Brebie `res, France) according to the
manufacturer’s instructions. EMSA was visualised by means of the LightShift
Mobility/Gel Shift Assay kit (Pierce). A volume of 2ml competitor double-
stranded oligonucleotide (0 to 4000 fmoles/ml) was added to a 16mlm i x
containing 1mlp o l y( d I dC), 2ml1 0  binding buffer and 3ml nuclear extract;
and incubated for 5min at room temperature. Thereafter, 2ml of labelled probe
(10fmoles/ml) was then added to the mixture and incubated for an additional
20min. In the case of supershift assays, antibody was added and the reaction
was further incubated for 45–60min. DNA–protein complexes were separated
by electrophoresis in a Novex DNA retardation gel (Invitrogen), transferred
onto a nitrocellulose membrane, and detected by means of the Chemilumi-
nescent Nucleic Acid Detection Module (Pierce). Anti-human RBP-L
(RBPSUHL) and anti-human HNF-1a antibodies were purchased from Inter-
chim (Montluc ¸on, France) and Tebu-bio (Le Perray en Yvelines, France),
respectively. The anti-Smad 1/5/8 antibody (Tebu-bio) was used as a control.
RESULTS
A SPINK1 promoter fragment drives reporter gene expression in
human COLO-357 cells
The human COLO-357 cell line was selected for use in the expression
assays on account of its pancreatic origin and because it has been
reported to express acinar digestive enzymes including trypsin, elastase
and chymotrypsin.25 In this study, using quantitative RT-PCR, we
demonstrated that the expression level of SPINK1 mRNA is compar-
able to that of CTRC mRNA in the COLO-357 cell line (Supplemen-
tary Table S2). The pGL3-SPINK1 wild-type construct, in which the
1171bp SPINK1 promoter insert (Figure 1a) was placed immediately
upstream of the luciferase reporter gene, induced a signiﬁcant increase
in luciferase activity in COLO 357 cells, but not in HEK 293 cells
(Figure 1b).
Determining the functionality of the SPINK1 promoter variants by
reporter gene assay
The 11 SPINK1 promoter variants to be tested were introduced into
the pGL3-SPINK1 plasmid by site-directed mutagenesis and the
resulting constructs were used to transfect COLO-357 cells. Based
upon their effect on luciferase expression, they could be allocated into
three distinct categories: (i) six variants (7T4G, 22C4T,
Table 1 Distribution of the 11 functionally characterised SPINK1
promoter variants in three screened populations
Franceb Germany India
Varianta Patient Control Patient Control Patientc Control
Neutral
–7T4G 0/213 0/550 0/418 0/379 0/439 0/316
–22C4T 0/213 0/550 0/418 1/379 0/439 0/316
–41G4A 0/213 0/550 0/418 0/379 0/439 0/316
–164G4C 1/213 1/550 0/418 0/379 0/439 0/316
–170G4A 1/213 0/550 0/418 0/379 0/439 0/316
–215G4Td 0/213 0/550 0/418 0/379 3/439 0/316
Loss-of-function
–53C4T 0/213 0/550 2/418e 1/379 0/439 0/316
–142T4C 1/213 0/550 1/418 0/379 2/439 0/316
–147A4G 1/213 0/550 2/418 1/379 0/439 0/316
Gain-of-function
–81C4T 0/213 0/550 0/418 0/379 0/439 0/316
–215G4Af 1/213 0/550 8/418 1/379 0/439 0/316
aVariants were classiﬁed functionally in accordance with the reporter gene assay results
obtained.
bChronic pancreatitis patients and controls did not include any individuals previously
described.20
cIncluding both tropical calciﬁc pancreatitis and idiopathic chronic pancreatitis patients (see
Supplementary Methods).
dFound in trans with the disease-predisposing SPINK1 N34S allele in all three heterozygous
carriers.21
eIncluding the one heterozygous carrier reported previously.3
fInvariably found in cis with IVS3+2T4C.
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termed functionally neutral, had no appreciable effect on luciferase
expression, (ii) three variants (53C4T, 142T4Ca n d147A4G)
caused between 20 and 46% decreases in luciferase expression (termed
loss-of-function); whereas (iii) two variants (81C4Ta n d
215G4A) resulted in B30% increases in luciferase expression
(termed gain-of-function) (Figure 1c).
Validating the reporter gene ﬁndings by EMSA
Of the six putatively neutral variants, 164G4C, 170G4Aa n d
215G4Twere selected for conﬁrmatory EMSAanalysis. The labelled
wild-type probe containing both 164G and 170G was not found to
form any speciﬁc complexes when incubated with COLO-357 nuclear
extract, as none of the shifted bands were affected by an increasing
molar excess of the SpC probe (Supplementary Figure 1). Thus, no
Figure 1 Functional characterization of SPINK1 promoter variants. (a) Partial sequence of the 5¢-ﬂanking region and beginning of the coding sequence
(underlined) of the human SPINK1 gene. The ﬁrst nucleotide of the translation initiation codon is numbered +1. The curved arrow indicates the transcription
initiation site. The 11 SPINK1 promoter variants under study are positioned in the sequence. Vertical dotted lines delimit the promoter region that had been
previously analysed by DNase I footprinting assay; the protein-protected regions I–III16 are shaded. The two downward dotted arrows delimit the fragment
that was used to construct the wild-type reporter gene plasmid, pGL3-SPINK1. The double underlined sequences within region IA and region II are the HNF1
and PTF1 recognition sequences characterized in this study. (b) The pGL3-basic vector and pGL3-SPINK1 (pSPINK1) were transfected into the HEK 293
and COLO 357 cells. Fireﬂy luciferase activity was measured and normalised against the co-transfected Renilla luciferase activity. The SPINK1 promoter-
driven gene expression is shown as a fold increase compared with that of the pGL3-basic vector. (c) Expression of wild-type (Wt) pGL3-SPINK1 and variant
constructs in COLO-357 cells. The effect of each variant on promoter activity is expressed as the ratio of normalised luciferase activity (against
co-transfected Renilla activity) to that of the Wt construct. Averaged ratios are from three to six independent experiments. Bars, SD. *Po0.05. **Po0.001.
***Po0.0001.
Table 2 Deﬁnition of terms related to EMSA
Term Abbreviation Deﬁnition
5¢-biotin end
labeled
Probe — Wild-type oligonucleotide duplex derived from the human SPINK1 promoter Yes
Speciﬁc competitor SpC As above No
Mutant competitor MuC As above but with the introduction of the variant of interest No
Irrelevant competitor IrC An oligonucleotide duplex corresponding to a sequence unrelated to the probe No
Cross competitor CrC An oligonucleotide duplex derived from a different gene that competes with the aforementioned probe
with respect to transcription factor binding
No
SPINK1 promoter variants
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binding to speciﬁc nuclear protein(s). The 215G4T variant will be
discussed at the end of this section.
By contrast, the labelled wild-type probes corresponding to the ﬁve
variants that manifested a functional effect upon reporter gene
expression all formed speciﬁc protein–DNA complexes when incu-
bated with COLO-357 nuclear extracts (Figures 2–5b). Thus, for
example, the complex (termed S1) formed between the labelled
53C probe (Figure 2a) and protein(s) in the COLO-357 nuclear
extracts may be regarded as speciﬁc, as its formation was inhibited by
the addition of a 25- to 200-fold molar excess of 53C SpC probe but
not by a 200-fold molar excess of IrC probe (lanes 3–7, Figure 2b). The
labelled 81C probe (Figure 3a) yielded four speciﬁc complexes;
whereas S2c and S2d were visible with a normal (short) exposure
time (lanes 2–6, Figure 3b), S2a and S2b were only visible after longer
exposure (lanes 2¢–6¢,F i g u r e3 b ) .
For each variant with a functional effect, we then compared the
ability of the MuC and SpC probes to compete with the labelled probe
for protein binding under the same conditions. In the cases of
53C4T (lanes 10–11, Figure 2b), 142T4Ca n d147A4G
(lanes 10–12, Figure 4b), the MuC probes were much less efﬁcient
at inhibiting speciﬁc complex formation than the corresponding SpC
probes. This indicates that all these variants have a markedly lower
afﬁnity for the cognate binding protein than for the wild-type allele.
Conversely, in the cases of 81C4T (lanes 10, 11 and 10¢,1 1 ¢;
Figure 3b) and 215G4A (lanes 11–12, Figure 5b), the MuC probes
were found to be more efﬁcient at inhibiting speciﬁc complex
formation than the corresponding SpC probes. This indicates that
in both cases, the variant alleles have a higher afﬁnity for their cognate
binding protein(s) than their wild-type counterparts.
The functionally neutral variant, 215G4T, affects the same
nucleotide as the abovementioned functional 215G4A variant.
However, the lack of any effect of the 215G4T variant on gene
expression is readily explicable in terms of its similar binding afﬁnity
for the cognate binding protein to that displayed by its wild-type
counterpart (lanes 11 and 13, Figure 5b).
Identiﬁcation of two cis-acting regulatory elements in the SPINK1
gene promoter
To obtain further insight into the mechanisms underlying those
variants with a demonstrable functional effect, we screened the
260 to 1 region of the SPINK1 5¢-regulatory region in silico
for transcription factor binding sites using MATCH (public version
1.0; http://www.gene-regulation.com/cgi-bin/pub/programs/match/
bin/match.cgi?), with the parameters ‘group of matrices: vertebrates’
and ‘cut-off selection for matrix group: to minimise false positives’.
The only hit obtained was a putative HNF1-binding sequence, 5¢-GTC
AATCATAAC-3¢ (Figure 1a), located within the previously deﬁned
region IA,16 which harbours the 142T4Ca n d147A4Gv a r i a n t s .
In addition, for each of the 11 promoter variants, a 21-bp sequence
tract, containing the variant plus 10-bp ﬂanking sequences on either
side, was screened using the same parameters, but no hits were
obtained. In short, the only relevant ﬁnding to emerge from this
search was that both the 142T4Ca n d147A4G variants were
predicted to disrupt the putative HNF1-binding sequence. This was
subsequently conﬁrmed in vitro by cross-competition and supershift
assays; speciﬁc complex (S3) formation between the labelled 142T/
147A probe and proteins in the COLO-357 nuclear extract was
inhibited by the human SI CrC (Figure 4c) and supershifted by the
anti-human HNF1a antibody (Figure 4d).
Based upon our current knowledge of promoter elements regulating
expression of secretory digestive enzyme genes, we also identiﬁed, by
visual inspection, a putative PTF1 bipartite sequence within region II
(Figure 3a). Further, the electrophoretic proﬁle of the four speciﬁc
complexes formed between the labelled 81C probe and COLO-357
nuclear extracts (Figure 3b) was found to be consistent with that of
PTF1 and its subunits.26 Hence, we surmised that S2a, S2b, S2c and
S2d might correspond to the PTF1 heterotrimer, the PTF1a (also
known as P48, a class B basic helix-loop-helix (bHLH) protein)/class
A bHLH protein heterodimer, RBP-J (a human homologue of the
Drosophila gene Suppressor of Hairless), and RBP-L (a paralogue of
RBP-J), respectively. To test this hypothesis, we performed cross-
competition analysis; a 400-fold molar excess of the human PRSS1
CrC probe signiﬁcantly inhibited S2d formation but increased S2a
formation (Figure 3c). It would thus seem that the CrC probe
preferentially bound free RBP-L, thereby leaving more labelled
81C probe available for PTF1 heterotrimer binding. We also carried
out a supershift assay using anti-human RBP-L antibody, which
signiﬁcantly reduced the intensity of the S2d complex (lane 4,
Figure 3d). By contrast, the S2d-speciﬁc complex was not supershifted
by a control antibody (lane 3, Figure 3d) nor was a control-speciﬁc
complex supershifted by the anti-human RBP-L antibody (lanes 5
and 6, Figure 3d). Taken together, these latter ﬁndings constituted
convincing evidence to support our contention that region II contains
a PTF1-binding sequence.
DISCUSSION
The foremost requirement for the appropriate functional analysis of
promoter variants is the use of a physiologically relevant cell line as an
expression system. Although it is known that the SPINK1 gene
impacts upon the CP phenotype through its function in human
Figure 2 Functional characterization of the 53C4T promoter variant.
(a) Sequences of the labelled probe, speciﬁc competitor (SpC) and mutant
competitor (MuC) used for EMSA. Only the sense strand of the double-
stranded oligonucleotide is shown. (b) EMSAs performed with labelled
probes incubated with COLO-357 nuclear extracts in the absence or
presence of SpC, MuC or irrelevant (Ir) competitor. S1 indicates the position
of the speciﬁc complex detected.
SPINK1 promoter variants
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available for in vitro experimentation. Consequently, we selected the
human pancreatic adenocarcinoma cell line COLO-357 as an alter-
native on the basis that it is known to express pancreatic acinar
enzymes such as trypsin, elastase and chymotrypsin.25 Here we
have further demonstrated, by means of quantitative RT-PCR analysis,
that the COLO-357 cells also express SPINK1. Indeed, the human
COLO 357 cell line displayed signiﬁcantly increased reporter
gene expression upon transfection with the pGL3-SPINK1 wild-type
construct (Figure 1b). Consequently, all further experiments were
performed in COLO-357 cells. This notwithstanding, it should
be pointed out that the expression level of SPINK1,a sw e l la st h a t
of the digestive enzymes in the COLO-357 cells, is certainly much
lower than that in their principal site of physiological expression,
human pancreatic acinar cells. Hence, to avoid any misleading con-
clusions emanating from the use of COLO-357 cells as an expression
system, we sought other means to validate the resulting functional
data, as described below.
Cross-correlating the results of reporter gene and EMSA analyses
with data from previous deletion mutagenesis and DNase I
footprinting studies
We ﬁrst attempted to see whether our functional data concurred with
ﬁndings from previous deletion mutagenesis and DNase I footprinting
studies.16 Of the 11 SPINK1 promoter variants functionally analysed
here, nine occurred within the 1t o179 region previously analysed
by DNase I footprinting. A perfect correlation was noted between
deduced functionality and location for these nine variants; all four
Figure 3 Functional characterization of the 81C4T promoter variant by EMSA and identiﬁcation of the cognate-binding protein. (a) Sequences of the
labelled probe, speciﬁc competitor (SpC) and mutant competitor (MuC). The sequence of the labelled probe or SpC corresponds precisely to the DNase I
footprinting-mapped region II (see Figure 1a). Underlined are the putative E box and TC box, components of the PTF1 bipartite recognition sequence. The
canonical PTF1-binding sequence is shown within the box. (b) EMSAs performed with labelled probes incubated with COLO-357 nuclear extracts in the
absence or presence of SpC, MuC or irrelevant (Ir) competitor with two exposure times. S2a, S2b, S2c and S2d indicate the four speciﬁc complexes
detected. (c) EMSA performed with the human PRSS1 cross-competitor (CrC) containing a putative PTF1-binding sequence. (d) Supershift assay performed
with the anti-human RBP-L antibody. A* Indicates anti-Smad 1/5/8 antibody used as control. P* indicates labelled –53C probe (see Figure 2a) used as a
control. The dotted arrow in lane 5 indicates the S1 complex formed between the labelled –53C probe and nuclear extracts (see also Figure 2b).
SPINK1 promoter variants
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142T4Ca n d147A4G, were located within protein-protected
regions, whereas all ﬁve putatively neutral variants (viz, 7T4G,
22C4T, 41G4A, 164G4Ca n d170G4A) were not
(Figure 1a). Consistent with this ﬁnding, EMSA revealed that although
the wild-type probes corresponding to the four functional variants
formed speciﬁc DNA–protein complexes when incubated with COLO-
357 nuclear extract, the wild-type probes corresponding to the neutral
164G4Ca n d170G4A( 7T4G, 22C4T, and 41G4Awere
not tested) variants did not. In the following discussion, we shall focus
speciﬁcally on the putative functional variants.
The 53C4T variant occurred within the DNase I footprinting-
mapped region III (Figure 1a). As position 60 represents the major
transcriptional initiation site,27 region III is likely to encompass the
core SPINK1 promoter that serves to position RNA polymerase II at
the correct site for transcriptional initiation to occur. Therefore, the
negative effect of the 53C4T variant on gene expression (Figure 1c)
is explicable simply in terms of the disruption of a positive regulatory
element within the core promoter.
The 142T4Ca n d147A4G variants occurred within region IA,
a previously deﬁned positive regulatory element within the SPINK1
promoter.16 In this study, we have provided deﬁnitive evidence that
these two variants caused a reduction in gene expression by disrupting
the SPINK1 HNF1-binding site, a site which is well conserved among
mammalian species (Supplementary Figure 2). HNF1 binds DNA as a
homo or heterodimer of two peptides, HNF1a and HNF1b,b o t h
Figure 4 Functional characterization of the 147A4Ga n d142T4C promoter variants by EMSA and identiﬁcation of the cognate-binding protein.
(a) Sequences of the labelled probe, speciﬁc competitor (SpC) and mutant competitors (MuCs). Underlined is a predicted HNF1 recognition sequence, of
which consensus sequence is shown within the box. (b) EMSAs performed with labelled probes incubated with COLO-357 nuclear extracts in the presence or
absence of SpC, MuCs or irrelevant (Ir) competitor. S3 indicates the speciﬁc complex detected. (c) EMSA performed with the human SI cross-competitor
(CrC) that contains an experimentally conﬁrmed HNF1-binding site. (d) Supershift assay carried out with the anti-human HNF1a antibody. S* denotes control
antibody. In b, c and d, only the informative data are shown.
Figure 5 Functional characterization of the 215G4Aa n d215G4T promoter variants by EMSA. (a) Sequences of the labelled probe, speciﬁc competitor
(SpC) and mutant competitors (MuC). (b) EMSAs performed with labelled probes incubated with COLO-357 nuclear extracts in the presence or absence of
SpC, MuCs or irrelevant (Ir) competitor. S4 indicates the speciﬁc complex detected. In b, only the informative data are shown.
SPINK1 promoter variants
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HNF1 is known to be abundantly expressed in the liver, intestine and
both exocrine and endocrine pancreatic cells,28 no HNF1-binding site
has so far been described in any gene encoding a secretory digestive
enzyme.
That both the 81C4Tand215G4A alleles cause a gain-of-function
(Figure 1c) and have a higher afﬁnity for their cognate binding
protein(s) than their wild-type counterparts (Figures 3b and 5b),
suggested that they should effect positive regulatory elements. Con-
sistent with this prediction, the 81C4T variant occurred within the
positive regulatory element in region II (Figure 1a); analysis of
previously reported deletion mutagenesis data16 revealed that variant
215G4A occurs within a positively acting region spanning 245 to
180. In addition, we were able to provide compelling evidence that
the 81C4T variant occurred within a PTF1-binding site in the
SPINK1 gene. PTF1 has a pivotal role in the development of the
pancreas and in the maintenance of the differentiated state of the adult
exocrine pancreas.26,29
In summary, the consistency observed between ﬁndings derived
from two entirely independent sources is strongly suggestive of the
validity of our conclusions.
Assessing the pathological relevance of SPINK1 promoter variants
through the combined consideration of functional and
epidemiological data
We then attempted to ascertain whether the results of the promoter
variant functional assays correlated with the available epidemiological
data. If we ﬁrst consider the three putatively neutral polymorphisms,
the 7T4Ga n d164G4C variants have been shown to occur
at comparable allele frequencies (B5–6%) in both patients and
controls in the Brazilian population,30 whereas the 41G4A
variant has been reported in both controls31 and patients32 in two
US studies. By sequencing 151 healthy subjects originating from
Cameroon, we identiﬁed the –41G4A variant in 44/151 (29.1%)
individuals (including three homozygotes) indicating that –41G4A
represents a common West-African variant (H Witt et al,u n p u b l i s h e d
data). In vitro functional analysis consistently showed that none
of these three polymorphisms affect reporter gene expression
(Figure 1c).
Let us now turn to the three variants (ie, 142T4C, 147A4G
and 215G4A) that occurred more frequently in patients than in
controls in at least two different populations (Table 1). The patho-
logical relevance of the ﬁrst two of these variants is strongly supported
by the observation that they both disrupt the HNF1-binding site
(Figure 4), thereby reducing SPINK1 gene expression (Figure 1c). At
ﬁrst sight, it would seem as if the gain-of-function exhibited by
215G4A (Figure 1c) is incompatible with the variant’s presumed
pathological role (Table 1). However, 215G4A is in complete
linkage disequilibrium with c.194+2T4C (IVS3+2T4C), a SPINK1
mutation that has been shown experimentally to cause exon 3
skipping both in vivo33 and in vitro.11 Clearly, any inﬂuence of the
215G4Av a r i a n to nSPINK1 gene expression would be completely
masked in vivo by the dramatic effect of the cis-linked c.194+2T4C
mutation on the mRNA splicing phenotype.
In similar vein two other variants, of which normal or elevated
function initially seemed to be at odds with their presumed patholo-
gical role turned out to be explicable in terms of the presence of
other allelic or non-allelic mutations in the patients concerned.
First, the gain-of-function 81C4T (Figure 1c), so far reported in
only a single patient,32 occurred in an individual who also harboured
the CFTR (MIM# 602421) p.F508del mutation on one allele and
the CFTR 5T allele of the intron 8 polyT tract on the other.
Compound heterozygotes for CFTR mutations comprising a highly
deleterious mutation on one allele (such as p.F508del) and a less severe
mutation on the other allele (such as intron 8 5T) have long been
known to display an increased risk of ICP (reviewed by Chen and
Fe ´rec6). Thus, somewhat ironically, the SPINK1 81C4T variant may
actually constitute a protective allele, the effect of which would have
been counteracted by the CFTR alleles in this particular case. The
second apparently anomalous case is the 215G4Tv a r i a n t ,w h i c h
was only detected in three Indian patients (Table 1). Taken together,
the reporter gene and EMSA data argue against the functionality of
this variant (Figures 1c and 5b), a conclusion supported by the ﬁnding
that all three subjects harbouring the 215G4T variant also pos-
sessed the SPINK1 allele with the N34S-containing haplotype, the
most frequent CP-predisposing factor, in trans.21 In stark contrast to
these cases, neither of the loss-of-function variants, 142T4Ca n d
147A4G, were known to reside either in cis or in trans to any
reported CP-associated mutations in the SPINK1, PRSS1, CTRC or
CFTR genes.
Thus, the above lines of evidence are generally supportive of the
functional data. In other words, the functional data obtained from the
COLO-357 cells proved to be highly informative with regard to the
pathogenesis of pancreatitis that is presumed to initiate in the acinar
cells of the pancreas. This makes the assessment of the pathogenic role
of the remaining three promoter variants relatively straightforward.
53C4T is a rare variant detected in 2/493 patients and 1/379
controls in Germany (Table 1). As it is located within the indispen-
sable core promoter and serves to reduce gene expression (Figure 1c),
53C4T is likely to be disease predisposing. Consistent with this
conclusion, 53C4Twas not known to lie either in cis or in trans to
any reported CP-associated mutations in the SPINK1, PRSS1, CTRC
or CFTR genes. The 22C4T variant was found in 2/40020 and
1/19031 control chromosomes but was detected in only 1/381 pan-
creatitis patients,32 not inconsistent with its apparent neutral effect on
reporter gene expression. Finally, the functionally neutral 170G4A
variant was only found in a single French patient (Table 1), which
might simply be a chance ﬁnding.
CONCLUSIONS
Despite the general difﬁculties inherent in promoter analysis17 and the
lack of any human pancreatic acinar cell lines in this speciﬁc case, we
succeeded in assessing the pathogenic relevance of the 11 currently
known SPINK1 promoter variants. On the basis of both functional
and epidemiological data, we concluded that only three variants
(ie, 53C4T, 142T4Ca n d147A4G) could reasonably be
deﬁned as CP-predisposing factors. This conclusion does not, how-
ever, exclude the participation of other genetic and environmental
factors in causing the disease. We may nevertheless reasonably pose
the question as to why a 20–40% decrease in SPINK1 gene transcrip-
tion (see Figure 1c) might increase the risk for CP when transcription
is upregulated 1000-fold under inﬂammatory conditions.34 The
answer may be that only the former contributes to disease initiation,
whereas the latter simply represents a late stage phenomenon. Finally,
the identiﬁcation of binding sites for two transcription factors, HNF1
and PTF1 within the SPINK1 promoter by virtue of their being
affected by speciﬁc variants would be further strengthened by HNF1
and PTF1 knockdown experiments such as the use of HNF1 and PTF1
siRNAs.
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